Why is cancer drug discovery so difficult?

Oncology has a higher rate of attrition in clinical development than most other therapeutic areas. Lengauer and colleagues discuss the factors responsible, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs. Thirty-five years after the &#...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Nature reviews. Drug discovery 2007-02, Vol.6 (2), p.115-120
Hauptverfasser: Kamb, Alexander, Wee, Susan, Lengauer, Christoph
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Oncology has a higher rate of attrition in clinical development than most other therapeutic areas. Lengauer and colleagues discuss the factors responsible, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs. Thirty-five years after the 'war on cancer' was declared, the discovery of anticancer drugs remains a highly challenging endeavour. Here, we consider the factors responsible, such as tumour heterogeneity, and suggest strategies to improve the chances of short-term success in the development of novel anticancer drugs.
ISSN:1474-1776
1474-1784
DOI:10.1038/nrd2155